Name: 生物技術板塊乘著疫苗推廣的浪潮而來 (Biotechnology sector rides wave of vaccine rollouts)
Uploaded: 2021-03-11T19:01:14.000Z
Duration: 6 min 14 s

你好，歡迎來到近距離的部門。

Focus today is biotechnology, and our guest is Patrick Healy, president of Caliber Financial Partners Reputation Early and financially, it has been a good year for biotechnology, especially drugmakers.

今天的焦點是生物技術，我們的嘉賓是Caliber Financial Partners聲譽早期和財務上的總裁Patrick Healy，這對生物技術，特別是製藥商來說是一個好年景。

The global race for a coronavirus vaccine has propelled some pharmaceutical companies to household names.

全球對冠狀病毒疫苗的爭奪，推動了一些藥企家喻戶曉。

And with billions more people to be inoculated, there are billions of dollars to be made.

而且還有幾十億人要接種，就有幾十億的資金可以賺。

This index, the NASDAQ Biotechnology Index, has managed to return 35% over the past year, although it is unchanged since the beginning of the year.

納斯達克生物技術指數這一指數雖然自年初以來沒有變化，但在過去的一年裡卻能獲得35%的回報。

Some of the names that make up this index you might recognize, such as AstraZeneca and Madonna.

構成這個索引的一些名字你可能認識，比如阿斯利康和麥當娜。

But as you can see, investing in biotech is not only about vaccines can also be risky for individual investors who do not benefit from detailed knowledge of these companies and their products dreams.

但正如你所看到的，投資生物技術不僅僅是疫苗，對於個人投資者來說也是有風險的，因為他們無法從對這些公司及其產品夢想的詳細瞭解中獲益。

讓我們問問口徑的金融合作夥伴。

Hey, Patrick, thank you so much for joining us.

嘿，帕特里克，非常感謝你加入我們。

Do you think the oversized returns for this sector, according to that index, is especially reliant on the pandemic?

根據該指數，你認為這個行業的超額收益，是否特別依賴疫情？

And will this trend hole this year well, 2020 obviously the covid, uh, pandemic has has dominated the news headlines and for good reason.

而這一趨勢將洞今年好，2020年很明顯，科維德，呃，大流行病已經佔據了新聞頭條，這是有充分理由的。

I'm impressed with how quickly pharma has really galvanized efforts and resources to finding treatments and a cure.

我印象深刻的是，製藥業已經真正激發了努力和資源來尋找治療方法和治癒方法。

But that being said, the biotech space is always one that, uh, is a good investable thesis in terms of outcomes, not just for covid, but for other terminal illnesses and hard to treat diseases.

但話說回來，生物技術領域始終是一個，呃，從結果來看是一個很好的可投資的論文，不僅僅是科維德，還有其他的絕症和難治疾病。

And so I do expect that to continue in 2010 now, Patrick, total deal values of bio farmer Therapeutics and MedTech companies fell by almost a third last year.

所以我預計2010年這種情況還會繼續，帕特里克，去年生物農民治療和醫療技術公司的總交易額下降了近三分之一。

According to a deal, former as big farmer focus on developing vaccines to fight and stem the pandemic.

根據協議，前作為大農專注於研發疫苗，以抗擊和遏制疫情。

Will this trend still be in play this year?

And how will it affect investment in this sector?

又將如何影響這個行業的投資？

Yeah, So I do think that a lot of the deal volume was put in the background during 2020 and for good reason.

是的，所以我確實認為很多交易量是在2020年期間放在後臺的，而且是有充分理由的。

Uh, the focus and priority was on, uh, finding a treatment for covid.

呃，重點和優先級是在，呃，找到治療covid的方法。

Um, that being said, I do think covid is going to be a seasonal, uh, issue.

嗯，說到這裡，我認為covid將是一個季節性的，呃，問題。

And so there will continue to be efforts dedicated to that.

是以，將繼續致力於這方面的工作。

But there are a number of other ailments and diseases that do not go away, and so the treatments will continue for those efforts.

但是還有一些其他的病痛和疾病是不會消失的，所以這些努力的治療還會繼續下去。

And I do think there's gonna be a lot of consolidation now that we're into 2021.

而且我確實認為現在進入2021年，會有很多整合。

It looks like we're making a lot of headway with Covid.

看來我們和Covid的合作有了很大的進展。

Now, aside from vaccines, what else should investors watch out for in this biotech space?

現在，除了疫苗，投資者在這個生物技術領域還應該注意什麼？

Yeah, so I spend a lot of time focusing on biotech, and I think it's It's a sector that's ripe for consolidation.

是的，所以我花了很多時間專注於生物技術， 我認為這是一個成熟的整合部門。

Uh, you have large format names that, um, look to acquire small and mid cap companies that have promising drug treatments.

呃，你有大格式的名字，嗯，尋找收購中小型公司，有前途的藥物治療。

I think that continues very expensive and time consuming to put a drug through clinical trials and ultimately commercialize it.

我認為，繼續將一種藥物通過臨床試驗並最終實現商業化非常昂貴和耗時。

And so if a farm that can inquiry a promising technology for small and mid cap name and a leapfrog that process replenish the pipeline for their drugs are going off patent, I think that will continue in 2021.

所以，如果一個農場能夠查詢到一個有前途的技術，為中小盤名目和一個飛躍性的技術，經由過程補充他們的藥物管道正在脫銷專利，我認為這種情況將在2021年持續。

Some of the areas that I think are most prevalent for consolidation oncology players are always hot.

我認為鞏固腫瘤玩家最普遍的一些領域一直是熱門。

It's very difficult to treat certain types of cancer.

某些類型的癌症是很難治療的。

And so that's an area that is often targeted for consolidation, immunotherapy, rare diseases, gene therapy, some of the breakthrough technology.

所以這也是一個經常被針對整合的領域，免疫治療，罕見病，基因治療，一些突破性的技術。

So given all that you've said, and if you're an investor that once exposure to this space, how would you invest?

所以鑑於你說的這些，如果你是一個投資者，一旦接觸到這個領域，你會如何投資？

Would you say focus on Big Farmer rather than the small appears?

你會說關注大農而不是小出現嗎？

Well, you have to define what type of investor you are.

好吧，你必須定義你是什麼類型的投資者。

If you're more of a risk averse value investor, then you're sticking to form of big pharma names.

如果你更傾向於風險厭惡型的價值投資者，那麼你就會堅持大藥廠的形式。

They tend to be more mature companies with more predictable cash flows.

他們往往是更成熟的公司，現金流更可預測。

A lot of them pay dividends, and so that's a good area, lets you sleep well at night.

很多人都有分紅，所以這是一個很好的領域，讓你晚上睡個好覺。

Um, if you're a bit more risk appetite than I think, the bigger opportunities are in the biotech sector, where they may be acquisition targets for a large farm, it comes with more volatility.

嗯，如果你的風險偏好比我想的要高一點，更大的機會是在生物技術領域，他們可能是一個大型農場的收購目標，它的波動性更大。

And so you have to understand that some of the early stage companies or mid stage companies they made developing a drug that, uh, there's binary outcome.

所以你要明白，一些早期的公司或者中期的公司，他們所做的開發藥物，呃，有二元的結果。

Either they get approved by the FDA or they don't and so you'll see a lot of volatility around those names.

要麼得到FDA準許，要麼不準許，所以你會看到這些名字周圍有很大的波動性。

So just be careful thanks very much, Patrick Healy there from caliber financial partners before I go here.

所以，只是要小心 非常感謝，帕特里克・希利有 從口徑金融合作夥伴之前，我去這裡。

Some of the top news in the sector the European Union's drugs regulator has given the green light to Johnson and Johnson's single dose Covid 19 vaccine as a block seeks to speed up its inoculation campaign.

部門的一些頂級新聞歐盟的藥物監管機構已經給強生和強生的單劑量Covid 19疫苗開了綠燈，因為塊尋求加快其接種活動。

The shot is the fourth to be endorsed in the EU after those made by Pfizer, AstraZeneca and Madonna.

該針劑是繼輝瑞、阿斯利康和麥當勞之後，第四個在歐盟認可的針劑。

Denmark and Norway have temporarily suspended the use of AstraZeneca shots after reports of the formation of blood clots in some who have been injected.

丹麥和挪威已暫時停止使用阿斯利康針劑，因為有報道稱一些被注射的人形成了血栓。

Denmark said the 14 day suspension was a quote, cautionary decision.

丹麥表示，14天的停賽是一個引以為戒的決定。

The move comes after Austria stopped using a batch of AstraZeneca shots while investigating a death, while the EU Medicines Agency said there was no evidence so far linking AstraZeneca to the Austria cases.

此前，奧地利在調查一起死亡事件時停止使用一批阿斯利康注射液，而歐盟藥品管理局則表示，至今沒有證據表明阿斯利康與奧地利案件有關聯。

Fighter will consider making its coronavirus vaccine outside the United States and Europe only after the pandemic supply phase is over, adding it is currently not talking to India over local production.

拳頭公司只有在流行病供應階段結束後，才會考慮在美國和歐洲以外的地方生產其冠狀病毒疫苗，並補充說，它目前沒有與印度就當地生產進行討論。

Sources told Reuters on Wednesday that the U.

消息人士週三告訴路透社，美國。

S drugmaker had told the Indian government it wanted to produce the vaccine locally, have assured faster approval and freedom on pricing and exports.

S製藥商曾告訴印度政府，它希望在當地生產疫苗，已經保證更快的準許和定價和出口的自由。

 That's your roundup of the biotech sector. 

這就是你對生物技術領域的總結。